Company news
Immutep Ltd news in 2016
Immutep Ltd's news releases, calls and decks from 2016, newest first.
Prima announces TACTI-mel clinical trial data
December 29, 2016
Prima announces AIPAC clinical trial data
December 21, 2016
Prima receives UK approval for AIPAC study
December 19, 2016
Wuxi & Prima sign MOU for strategic partnership
November 22, 2016
S&P DJ Indices Announces March Quarterly Review
November 7, 2016
S&P DJ Indices Announces March Quarterly Rebalance
November 6, 2016
Appendix 4E & 2016 Full Year Statutory Accounts
August 31, 2016
European Patent Grants for IMP731 Antibody
August 24, 2016
PRR Collaborates In New Clinical Trial For Imp321
July 12, 2016
First Data From Phase IIb Clinical Trial of Imp321
June 21, 2016
Prima BioMed Files U.S Shelf Registration Statement
May 29, 2016
PRR Enters Agreement with Sydys to Advance CVac Program
May 12, 2016
Japanese Patent Grants For IMP321 In Cancer
May 1, 2016
Appendix 4C - quarterly March 2016
April 8, 2016
Proposed Acquisition of Immutep
March 30, 2016
First patient dosed in AIPAC
March 2, 2016
US patent granted for IMP731 antibody
February 11, 2016
Prima initiates Phase I melanoma study in Australia
February 10, 2016
Decks in 2016
- Prima BioMed — Shareholder Meeting (November 2016)
Shareholder meeting · 27 slides · Nov 28, 2016
- Prima BioMed — SITC 2016 (Society for Immunotherapy of Cancer), National Harbor, MD
Conference · 5 slides · Nov 14, 2016